| Agente terapéutico del cáncer de ovario. |
El cáncer de mama y de ovario es un grave problema de salud pública que supone una grave amenaza para las mujeres.. En los últimos años, La creciente tasa de incidencia del cáncer de mama en China fue incluso 1-2% mayor que el de los países con alta incidencia. Por otro lado, El cáncer de ovario sigue siendo el desafío más grave para el oncólogo ginecológico porque actualmente no se dispone de un enfoque maduro para el diagnóstico en etapa temprana.. Tras el diagnóstico, acerca de 70% Los casos están en etapa avanzada.. Incluso sometiéndolos a un tratamiento eficaz y consiguiendo un alivio completo, todavía hay 70% de pacientes que tendrán problemas de recurrencia con una tasa de supervivencia a 5 años rondando 30-40%. Por lo tanto, Las personas intentan establecer medidas de prevención y control de tres niveles del cáncer de ovario como otras enfermedades crónicas..
Existe una necesidad urgente de un nuevo medicamento para el tratamiento del cáncer de ovario porque la quimioterapia basada en platino tiene una duración limitada del fármaco antes de que se produzcan efectos secundarios intolerables.. Tómalo, junto con otros inhibidores de PARP en desarrollo, son preparaciones orales que pueden ser mejor toleradas y pueden tener aplicaciones a más largo plazo en comparación con los medicamentos utilizados en la quimioterapia convencional.. Olaparib puede prevenir una enzima que participa en la reparación celular, y es adecuado para pacientes con ciertas mutaciones genéticas. El fármaco también tiene buenas perspectivas en el tratamiento de otros cánceres., abriendo considerables oportunidades de mercado para olaparib.
En diciembre 19, 2014, the FDA approved novel anti-cancer drug olaparib (Lynparza) for monotherapy to the patients of advanced ovarian cancer who has undergone at least 3 rounds of chemotherapy or patients of suspected BRCA mutations. Al mismo tiempo, FDA approved the quantitation and classification of diagnostic kits for the detection of mutations in BRCA1 and BRCA2, BRACAnalysis CDx. Tómalo (Lynparza) is the first PARP inhibitor drugs which has been approved by FDA.
En febrero 2, 2015, the European Union Food and Drug Administration (EMA) also approved olaparib to enter into market in the 28 countries of European Union including Iceland, Liechtenstein and Norway. But the indications of EMA and FDA approved are slightly different; the former is for the BRCA gene mutation cases, and also for the maintenance therapy for patients of advanced epithelial ovarian cancer who has previously received platinum-containing chemotherapy drugs and exhibit response and subject to recurrence. |
| Efectos farmacológicos |
Olaparib is a kind of novel poly ADP-ribose polymerase (PARP) inhibidores, incluyendo PARP1, PARP2, and ARP3. PARP mediates a DNA-repair mechanism which plays a important role in DNA damage repair and apoptosis, so olaparib specifically targets on the DNA repair mechanism of the targeting cell DNA repair and take effects by attacking the critical vulnerabilities of cancer cells carrying mutations in BRCA1 and BRCA2. Owing to this mechanism, it can be used for the maintenance therapy of patients of severe recurrent ovarian cancer who has breast cancer susceptibility gene (BRCA) mutation as well as being sensitive to platinum drug.
Scientists from Harvard Medical School Dana-Farber Cancer Institute have found that the target site of olaparib is the polymerase Q (POLQ, also known POLθ). Those scientists found that a large number of patients of ovarian cancer has the genetic deficiency in the homologous recombination (homologous recombination, HR) repair pathway and dramatic up-regulated expression of POLQ greatly. Since HR is an important repair pathway for repairing broken DNA, they speculated that the major function of POLQ is to compensate for the lack of HR and participate in DNA repair.
The experiment has demonstrated that, in normal HR cells, knockout of POLQ would make HR activity increase significantly; while in HR deficient cells, the knockout of POLQ leads to cell death. POLQ contains RAD51 binding domain which can block the process of RAD51-mediated DNA repair. Related research has been published in the February 12, 2015 journal with Raphael Ceccaldi being the first author of this research.
Studies have revealed that about 10% of ovarian cancer patients and 5% of breast cancer patients contain BRCA1 or BRCA2 mutations. Both BRCA1 and BRCA2 belong to tumor suppressor genes as the major components of HR repair pathway. Their mutation suggests the loss of function for the HR repair pathway. In the cancer model of BRCA1 or BRCA2 mutations, blocking the important component for repairing single-strand DNA breaks–PARP can kill the mutated cancer cells. Put the BRCA-deficient mice with POLQ deficient mice for hybridization will cause the death of mouse embryos shortly after birth, which means that the coexistence of two repair pathway deficiency will cause embryonic lethality.
These above findings suggest that olaparib, a kind of novel oral PARP inhibitor which is able to kill BRCA deficient cells, may be the effective drug for treating cancer patients who carry such mutations. Previamente, researcher’s knowledge of the BRCA mutation hasn’t influenced patients’ choice of treatment on either ovarian cancer or breast cancer. Sin embargo, after the study, which means that olaparib can be used for the targeted therapy of cancer patients who carries BRCA1 or BRCA2 gene mutations with the therapeutic target site being the genetic deficiency of cancer cell genetic defect rather than a target organ.
In ovarian and breast cancer cells, BRCA mutations are the first heavy blow to the survivability of cell because it increases their susceptibility to DNA damage. Through targeting the PARP-controlled adjuvant repair pathways, olaparib and its similar drugs achieve the second heavy blow to the survivability of cell. With the disorders of both of the two repairmen signaling pathways, the accumulation of DNA damage exert the third heavy blow to the cells. |
| Farmacocinética |
Absorción
After the oral administration of olaparib through its capsule preparation, it is quickly absorbed with the plasma concentration typically reaching peak at 1-3 hour period after the administration. Multiple rounds of administration cause no significant savings (savings ratio 1.4-1.5 con 2 veces por día) with achieving steady-state exposure within 3 a 4 dias.
Limited information suggest that, in dose across the range of 100 a 400 mg, the increase of whole body exposure (AUC) olaparib is less than direct proportion but the PK data across the test is variable.
The co-administration of a high-fat meal causes a lower absorption rate (Tmax is delayed by 2 horas), but doesn’t significantly alter the extent of absorption of olaparib (mean AUC increased by about 20%).
Distribución
After the administration of a single dose of 400 mg olaparib, the steady-state olaparib has a mean (±SD) apparent volume of distribution of 167 ± 196 L. After the achievement of the plasma concentrations at the dose of 400mg twice daily, the in vitro protein binding rate of olaparib is approximately 82%.
Metabolismo
In vitro, CYP3A4 has been shown to be primary enzymes responsible for metabolism of olaparib.
After oral administration of 14C-olaparib to female patients, unchanged olaparib accounts for the majority (70%) of the circulating radioactivity in the plasma.
It is extensively metabolized in the urine and feces with the radioactivity of drug remained unchanged accounting for 15% Estanozolol semielaborado de la serie líquida de esteroides 6%, respectivamente. The biggest part of metabolism attributes to the oxidation and the derived components which subsequently bind with glucuronide or sulfate.
Excretion
After the administration of a single dose of 400 mg olaparib, it was observed of a mean (± standard deviation) terminal plasma half-life being 11.9 ± 4.8 in hours and the apparent plasma clearance being 8.6 ± 7.1L/h.
After a single dose of 14C-olaparib, during the seven days of collection, 86% of the administered radioactivity was recovered with 44% going through urine and 42% going through feces. Most of the material is excreted as metabolites.
According to the preliminary data of special efforts from renal impairment test, when olaparib is administrated by patients of mild renal impairment (CLcr = 50-80 mL/min; N = 14) and compared to patients with normal renal function (CLcr> 80 mL/min; N = 8), the mean AUC and Cmax of olaparib were increased by 1.5 Estanozolol semielaborado de la serie líquida de esteroides 1.2 veces, respectivamente. There are no data available for the patients with CLcr <50 mL/min or patients subjecting to dialysis. |
| Interacciones farmacológicas |
In vitro, olaparib is a inhibitor of the CYP3S4 but the inducing agent of CYP2B6 upon the higher concentration achieved clinically. Olaparib has small or no inhibitory effects on other CYP isozymes. In vitro studies have ever shown that olaparib is the substrate of CYP3A4.
According from a set of Drug-interaction test data (N = 57), when olaparib is administrated with itraconazole, a potent CYP3A inhibitor, in combination, the AUC and Cmax of olaparib were increased by 2.7-and 1.4-fold, respectivamente. The stimulation based on the physiologically pharmacokinetic (PBPK) model suggests a moderate inhibitor of CYP3A (fluconazole) can increase the AUC and Cmax of olaparib, respectivamente, by 2-and 1.1-fold.
According a set of Drug-interaction test data (N = 22), when olaparib is administrated with rifampicin, a potent CYP3A inducer, in combination, the AUC and Cmax of olaparib were reduced by 87% Estanozolol semielaborado de la serie líquida de esteroides 71 %, respectivamente. Stimulation based on PBPK model suggests one kind of moderate CYP3A inducers (efavirenz) may reduce the AUC and Cmax of olaparib by 50-60% Estanozolol semielaborado de la serie líquida de esteroides 20-30%, respectivamente.
In vitro studies have ever shown that olaparib is the substrate of P-gp and the inhibitors of BCRP, OATP1B1, OCT1, OCT2, OAT3, MATE1 and MATE2K. It is still not clear about the clinical relevance of these findings.
La información anterior es editada por Chemicalbook of Dai Xiongfeng. |
| Efectos secundarios |
1. The most common adverse reaction in clinical trials≥20%) include anemia, náuseas, fatiga (including lack in strength), vómitos, diarrea, taste disturbance, indigestión, dolor de cabeza, pérdida de apetito, nasopharyngitis/pharyngitis/URI, tos, arthralgia/musculoskeletal pain, myalgia, dolor de espalda, dermatitis/rash and abdominal pain/discomfort.
2. The most common laboratory abnormalities (≥25%) is increased creatinine, increased red blood cell mean volume, reduced hemoglobin, reduced lymphocytes, reduced absolute neutrophil count, and thrombocytopenia. |
| Propiedades químicas |
Blanco sólido |
| Usos |
Olaparib es un potente poli(ADP-ribosa) polimerasa (PARP) inhibidor. Se ha demostrado que olaparib induce una destrucción significativa de células tumorales linfoides deficientes en ATM in vitro e in vivo.. Estudios recientes muestran que Olaparib aumenta la radiosensibilidad de un xenoinjerto de tumor de pulmón, lo que lo convierte en un candidato potencial para su uso en combinación con radioterapia. |
| Definición |
Chebi: A member of the class of N-acylpiperazines obtained by formal condensation of the carboxy group of 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)metilo]benzoic acid with the free amino group of N-(cyclpropylcarbonyl)pi erazine; used to treat advanced ovarian cancer. |
| Usos |
Many of the products generated by alkylating agents on DNA can be efficiently repaired by normal base excision repair (BER). Some poly(ADP-ribosa) polymerases (PARPs) assist in the repair of single-strand DNA nicks, an important step in BER. Olaparib is a potent inhibitor of PARP1 and PARP2 (IC50 = 5 Estanozolol semielaborado de la serie líquida de esteroides 1 Nuevo Méjico, respectivamente) but is less effective against the PARP tankyrase-1 (IC50 = 1.5 μm). It can be used in cells and in animals, alone or in combination therapy with alkylating agents, to block BER and increase cancer cell death.[Cayman Chemical] |
Gerente de ventas